Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 501–600 of 1,002
A Lipid Gate for the Peripheral Control of Pain
Piomelli, D., Hohmann, A. G., Seybold, V. S., & Hammock, B. D. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3475-14.2014 · Cited by 68
“The effects of the NAAA inhibitor ARN077 on DRG neurons parallel those of URB597 but are mechanistically different in that they require PPAR- rather than CB1 receptors (Khasabova et al., 2012).”
BackgroundInfluentialSelf-citationThe role of CB 1 in intestinal permeability and inflammation
Karwad, M. A., Couch, D. G., Theophilidou, E., Sarmad, S., Barrett, D. A., Larvin, M., Wright, K. L., Lund, J. N., & O'Sullivan, S. E. (2017) · The FASEB Journal · doi:10.1096/fj.201601346r · Cited by 60
“Because URB597 and JZL184 do not activate CB1 (32, 33), this suggests that accumulation of endogenously producedAEAand2-AGat theapical epithelial layer increase permeability via CB1 (16).”
Zebrafish models relevant to studying central opioid and endocannabinoid systems
Demin, K. A., Мешалкина, Д. А., Kysil, E. V., Antonova, K. A., Volgin, A. D., Yakovlev, O. A., Alekseeva, P. A., Firuleva, M. M., Lakstygal, A. M., de Abreu, M. S., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.024 · Cited by 68
Cascio, M. G., Minassi, A., Ligresti, A., Appendino, G., BURSTEIN, S. H., & Marzo, V. D. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.075 · Cited by 67
Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain
Astarita, G., Ahmed, F., & Piomelli, D. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700354-jlr200 · Cited by 68
Self-citationManduca, A., Servadio, M., Campolongo, P., Palmery, M., Trabace, L., Vanderschuren, L. J. M. J., Cuomo, V., & Trezza, V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.009 · Cited by 66
“Drug dose and pre-treatment intervals were based on literature (Hill et al., 2007; Kathuria et al., 2003; Naidu et al., 2007; Trezza et al., 2012b; Trezza and Vanderschuren, 2008) and on pilot experiments.”
BackgroundMethodInfluentialSelf-citationWise, L. E., Long, K. A., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200130s · Cited by 64
Ethanolamine is a novel STAT-3 dependent cardioprotective agent
Kelly-Laubscher, R. F., Lamont, K. T., Somers, S., Hacking, D., Lacerda, L., Thomas, P., Opie, L. H., & Lecour, S. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0125-0 · Cited by 66
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH)
Johnson, D. S., Ahn, K., Kesten, S., Lazerwith, S. E., Song, Y., Morris, M., Fay, L., Gregory, T., Stiff, C., Dunbar, J. B., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.080 · Cited by 64
Boldrup, L., Wilson, S. J., Barbier, A., & Fowler, C. J. (2004) · Journal of Biochemical and Biophysical Methods · doi:10.1016/j.jbbm.2004.04.020 · Cited by 74
Drug Design for Neuropathic Pain Regulation from Traditional Chinese Medicine
Tou, W. I., Chang, S., Lee, C.-C., & Chen, C. Y. (2013) · Scientific Reports · doi:10.1038/srep00844 · Cited by 65
A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening
Ramarao, M. K., Murphy, E. A., Shen, M. W. H., Wang, Y., Bushell, K. N., Huang, N., Pan, N., Williams, C. M. M., & Clark, J. D. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.04.032 · Cited by 68
Discovery of Boronic Acids as Novel and Potent Inhibitors of Fatty Acid Amide Hydrolase
Minkkilä, A., Saario, S. M., Käsnänen, H., Leppänen, J., Poso, A., & Nevalainen, T. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801051t · Cited by 65
The Endocannabinoid Anandamide Inhibits the Function of α4β2 Nicotinic Acetylcholine Receptors
Spivak, C. E., Lupica, C. R., & Öz, M. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.036939 · Cited by 69
“To prevent possible hydrolysis of AEA to arachidonic acid by fattyacid amide hydrolase, 1 M URB 597, the specific and potent fatty-acid amide hydrolase inhibitor (Kathuria et al., 2003) was included in the patch pipette.”
MethodKhasabova, I. A., Xiong, Y., Coicou, L. G., Piomelli, D., & Seybold, V. S. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0130-12.2012 · Cited by 65
“Although PEA is a substrate for FAAH (Lichtman et al., 2002; Kathuria et al., 2003), the FAAH inhibitor URB597 (cyclohexylcarbamic acid 3’-carbamoylbiphenyl-3-yl ester) does not alter the level of endogenous PEA in DRG cells under the same conditions that produce more than a twofold increase in AEA…”
BackgroundSelf-citationFichna, J., Sałaga, M., Stuart, J. M., Saur, D., Sobczak, M., Zatorski, H., Timmermans, J., Bradshaw, H. B., Ahn, K., & Storr, M. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12272 · Cited by 64
Cocaine- and amphetamine related transcript (CART) and anxiety
Stanek, L. M. (2006) · Peptides · doi:10.1016/j.peptides.2006.01.027 · Cited by 68
Hájos, N., Kathuria, S., Dinh, T. P., Piomelli, D., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03433.x · Cited by 64
Self-citationDesroches, J., Guindon, J., Lambert, C., & Beaulieu, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.322 · Cited by 63
“, 2005) and selective FAAH inhibitors such as URB597 (Kathuria et al., 2003; Jayamanne et al., 2006) have been described.”
BackgroundMethodInfluentialHou, L., Rong, J., Haider, A., Ogasawara, D., Varlow, C., Schafroth, M. A., Mu, L., Gan, J., Xu, H., Fowler, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01459 · Cited by 51
Puente, N., Elezgarai, I., Lafourcade, M., Reguero, L., Marsicano, G., Georges, F. E., Manzoni, O. J., & Grandes, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008869 · Cited by 66
Sasso, O., Migliore, M., Habrant, D., Armirotti, A., Albani, C., Summa, M., Moreno‐Sanz, G., Scarpelli, R., & Piomelli, D. (2015) · The FASEB Journal · doi:10.1096/fj.15-270637 · Cited by 63
“Discovery of a potent FAAH/Cox inhibitor The existence of structural commonalities between the alkyl carbamic acid biphenyl-3yl-ester class of FAAH inhibitors such as URB597 (23) and members of the 2-arylpropionic acid class of NSAIDs such as flurbiprofen (29) allowedus toutilize a framework combination strategy (30)…”
BackgroundMethodInfluentialSelf-citationEndocannabinoid signaling in social functioning: an RDoC perspective
Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.169 · Cited by 62
Fatty acid amide hydrolase inhibitors: a patent review (2009 – 2014)
Lodola, A., Castelli, R., Mor, M., & Rivara, S. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1067683 · Cited by 67
“6 nM; human FAAH kinact/Ki = 1,590 M -1 s) [24,37], able to block FAAH activity through irreversible carbamoylation of the catalytic nucleophile Ser241 [38], with its biphenyl moiety serving as the leaving group.”
BackgroundSelf-citationActivation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats
Martinez, A. A., Morgese, M. G., Pisanu, A., Macheda, T., Paquette, M. A., Seillier, A., Cassano, T., Carta, A. R., & Giuffrida, A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.024 · Cited by 69
“In previous studies, we showed that direct activation of cannabinoid CB1 receptors alleviated rat AIMs [1, 16, 17], whereas elevation of the endocannabinoid anandamide via inhibition of its degradation by URB597 (URB) [18, 19] ameliorated AIMs only when URB was co-administered with the TRPV1 antagonist capsazepine (CP…”
BackgroundMarco, E. M., Adriani, W., Canese, R., Podo, F., Viveros, M., & Laviola, G. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.10.006 · Cited by 69
Optimization of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase
Kimball, F. S., Romero, F. A., Ezzili, C., Garfunkle, J., Rayl, T. J., Hochstatter, D. G., Hwang, I., & Boger, D. L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701210y · Cited by 67
Parker, L. A., Limebeer, C. L., Rock, E. M., Litt, D., Kwiatkowska, M., & Piomelli, D. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.014 · Cited by 66
“That is, URB can magnify the hypothermic response produced by AEA [18] and produce anxiolyticlike responses in both the zero-maze test and the isolation-induced ultrasonic vocalization test when administered 2 h before behavioral testing [21].”
BackgroundSelf-citationSmaga, I., Bystrowska, B., Gawliński, D., Pomierny, B., Stankowicz, P., & Filip, M. (2014) · Neurotoxicity research · doi:10.1007/s12640-014-9465-0 · Cited by 54
“*p \ 0.05; **p \ 0.01; ***p \ 0.001 versus corresponding vehicle manner in which an increase of AEA levels lasts between 30 min and 2 h while PEA/OEA levels are maintained up to 6 h (the present paper; Kathuria et al. 2003; Fegley et al. 2005; Piomelli et al. 2006).”
InfluentialAntiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?
Moreira, F. A., Aguiar, D. C., Campos, A. C., Lisboa, S. F., Terzian, A. L., Resstel, L. B., & Guimarães, F. S. (2009) · Neural Plasticity · doi:10.1155/2009/625469 · Cited by 61
Long, J. Z., Jin, X., Adibekian, A., Li, W., & Cravatt, B. F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016976 · Cited by 62
Yuan, Y., Wang, F., Tang, W., Ding, Z., Wang, L., Liang, L., Zheng, Z., Zhang, H., & Liang, G. (2016) · ACS Nano · doi:10.1021/acsnano.6b03412 · Cited by 64
Tarzia, G., Duranti, A., Gatti, G., Piersanti, G., Tontini, A., Rivara, S., Lodola, A., Plazzi, P. V., Mor, M., Kathuria, S., et al. (2005) · ChemMedChem · doi:10.1002/cmdc.200500017 · Cited by 70
Self-citationMaldonado, R. J., & Valverde, O. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.001 · Cited by 67
Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases
Mallat, A., Teixeira-Clerc, F., Deveaux, V., & Lotersztajn, S. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.403 · Cited by 62
“Finally, preclinical studies recently identified FAAH inhibitors as compounds with potential applications as analgesics and antidepressants [27,28].”
BackgroundBashashati, M., Storr, M., Nikas, S. P., Wood, J., Godlewski, G., Liu, J., Ho, W., Keenan, C. M., Zhang, H., Alapafuja, S. O., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01644.x · Cited by 66
“catalepsy) are not observed in animals treated with FAAH inhibitors or seen in mice deficient in the FAAH gene (Cravatt et al., 2001; Kathuria et al., 2003).”
BackgroundLysenko, L. V., Kim, J., Henry, C. L., Tyrtyshnaia, A. A., Kohnz, R. A., Madamba, F., Simon, G. M., Kleschevnikova, N., Nomura, D. K., Ezekowitz, R. A. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114521 · Cited by 66
“For example, Ts65Dn mice tested in the ‘marble burying’ assay, a test for compulsive behavior and anxiety, showed no effect with a low dose of JZL184 (4–8 mg/kg) but a decrease in burying activity with a higher dose (40 mg/kg), while genetic deletion or pharmacological inhibition of FAAH, which selectively increased l…”
BackgroundSex differences in hippocampal response to endocannabinoids after exposure to severe stress
Zer‐Aviv, T. M., & Akirav, I. (2016) · Hippocampus · doi:10.1002/hipo.22577 · Cited by 65
El-Gohary, M., & Eid, M. A. E.-W. (2004) · Human & Experimental Toxicology · doi:10.1191/0960327104ht426oa · Cited by 65
Fichna, J., Wood, J. T., Papanastasiou, M., Vadivel, S. K., Oprocha, P., Sałaga, M., Sobczak, M., Mokrowiecka, A., Cygankiewicz, A. I., Zakrzewski, P. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085073 · Cited by 60
“However, behavioral side effects typical for CB agonists are absent only in animals treated with selective FAAH [23,24], but not selective MAGL or mixed FAAH/MAGL inhibitors [25–27].”
BackgroundModulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system
Starowicz, K., & Przewłocka, B. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0392 · Cited by 64
Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System
Saario, S. M., Poso, A., Juvonen, R. O., Järvinen, T., & Salo‐Ahen, O. M. H. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060394q · Cited by 60
The Increasing Role of QM/MM in Drug Discovery
Lodola, A., & Vivo, M. D. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-398312-1.00011-1 · Cited by 60
Therapeutic Potential of Endocannabinoid‐Hydrolysing Enzyme Inhibitors
Saario, S. M., & Laitinen, J. T. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00130.x · Cited by 67
Sulfonyl Fluoride Inhibitors of Fatty Acid Amide Hydrolase
Alapafuja, S. O., Nikas, S. P., Bharathan, I., Shukla, V. G., Nasr, M. L., Bowman, A. L., Zvonok, N., Li, J., Shi, X., Engen, J. R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301205j · Cited by 66
Han, B., Wright, R., Kirchhoff, A. M., Chester, J. A., Cooper, B. R., Davisson, V. J., & Barker, E. L. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.09.031 · Cited by 59
“0 mg/kg in an injection volume of 5 ml/kg [21].”
Role of the endogenous cannabinoid system in nicotine addiction: novel insights
Gamaleddin, I., Trigo, J. M., Gueye, A. B., Zvonok, A. M., Makriyannis, A., Goldberg, S. R., & Foll, B. L. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00041 · Cited by 63
“carbamic acid 3-carbamoyl-3-yl ester (URB597) produce elevation of anandamide levels by blocking anandamide reuptake or by inhibiting FAAH, respectively (105, 106).”
BackgroundCross-Mellor, S. K., Ossenkopp, K., Piomelli, D., & Parker, L. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0589-7 · Cited by 63
“2005) and produce anxiolytic-like responses in both the zero-maze test and the isolation-induced ultrasonic emission test when administered 2 h before the behavioral test (Kathuria et al. 2003).”
BackgroundMethodSelf-citationTargeting the cannabinoid system for pain relief?
Chiou, L., Hu, S. S., & Ho, Y. (2013) · Acta anaesthesiologica Taiwanica · doi:10.1016/j.aat.2013.10.004 · Cited by 68
Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation
Gyires, K., & Zádori, Z. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160303110150 · Cited by 62
“psychoactive effects (such as catalepsy, hypothermia, or hyperphagia) than the direct stimulants of CB1 receptors [30], while the beneficial effects due to activation of CB1 and/or CB2 receptors would be retained [31].”
Bisogno, T., & Marzo, V. D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.002 · Cited by 68
Degroot, A., & Nomikos, G. G. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03556.x · Cited by 58
“In this regard, it is noteworthy that anxiolytic effects of fatty acid amide hydrolase inhibitors in passive avoidance tests have recently been demonstrated by Kathuria et al. (2003).”
BackgroundTang, X., Edwards, E. M., Holmes, B. B., Falck, J. R., & Campbell, W. B. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00491.2005 · Cited by 56
“Diazoarachidonyl ketone (DAK; 10 M) and URB-532 (10 M) were synthesized as previously described (16, 28).”
MethodKerr, D. M., Burke, N. N., Ford, G. K., Connor, T., Harhen, B., Egan, L. J., Finn, D. P., & Roche, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.032 · Cited by 66
“The present study investigated the effect of the selective FAAH inhibitor URB597 (Kathuria et al., 2003; Fegley et al., 2005; Piomelli et al., 2006), on LPS-induced changes in cytokine expression in the hypothalamus, an important site of cytokine-mediated regulation of physiological function and…”
InfluentialScherma, M., Muntoni, A. L., Melis, M., Fattore, L., Fadda, P., Fratta, W., & Pistis, M. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4196-3 · Cited by 60
Fowler, C. J. (2006) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00442.x · Cited by 57
Modulation of defensive behavior by transient receptor potential vanilloid type-1 (TRPV1) channels
Aguiar, D. C., Moreira, F. A., Terzian, A. L., Fogaça, M. V., Lisboa, S. F., Wotjak, C. T., & Guimaraes, F. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.026 · Cited by 57
Targeting the endocannabinoid system in treating brain disorders
Bahr, B. A., Karanian, D. A., Makanji, S. S., & Makriyannis, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.4.351 · Cited by 63
“The FAAH inhibitors as well as FAAH-knockout strategies have been shown to enhance cannabinergic signalling through CB1 receptors [25,67,117].”
BackgroundNiphakis, M. J., Johnson, D. S., Ballard, T. E., Stiff, C. M., & Cravatt, B. F. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200089j · Cited by 69
Fowler, C., Naidu, P., Lichtman, A. H., & Onnis, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00029.x · Cited by 57
“, 2006), nor other markers of a general central CB1 receptor activation (Kathuria et al., 2003).”
BackgroundCampos, A. C., Ferreira, F. R., Silva, W. A., & Guimarães, F. S. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.016 · Cited by 57
Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119
Hassing, H. A., Fares, S., Larsen, O., Pad, H., Hauge, M., Jones, R. M., Schwartz, T. W., Hansen, H. S., & ROSENKILDE, M. M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.08.018 · Cited by 62
Leishman, E., Manchanda, M., Thelen, R., Miller, S., Mackie, K., & Bradshaw, H. B. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0031 · Cited by 61
Myllymäki, M. J., Saario, S. M., Kataja, A. O., Castillo‐Melendez, J. A., Nevalainen, T., Juvonen, R. O., Järvinen, T., & Koskinen, A. M. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070501w · Cited by 57
“Compounds 13 , 15 , 18 , 22 , 23 , and 26 inhibit FAAH with IC 50 values (32 - 56 nM) almost equal to that obtained for compound 14 .”
BackgroundResultTsuboi, K., Okamoto, Y., Rahman, I. A. S., Uyama, T., Inoue, T., Tokumura, A., & Ueda, N. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.01.002 · Cited by 58
The Endocannabinoid System and Anxiety
Lisboa, S. F. D. S., Gomes, F. V., Terzian, A. L. B., de Aguiar, D. C., Moreira, F. A., Resstel, L. B. M., & Guimarães, F. S. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.09.006 · Cited by 65
Sloan, M. E., Gowin, J. L., Yan, J., Schwandt, M. L., Spagnolo, P. A., Sun, H., Hodgkinson, C. A., Goldman, D. A., & Ramchandani, V. A. (2017) · Addiction Biology · doi:10.1111/adb.12491 · Cited by 58
“This accords with studies showing increased anandamide levels and ethanol intake when FAAH is pharmacologically inhibited (Kathuria et al. 2003; Blednov et al. 2007; Hansson et al. 2007; Vinod et al. 2008).”
BackgroundColangeli, R., Pierucci, M., Benigno, A., Campiani, G., Butini, S., & Giovanni, G. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-11606-1 · Cited by 62
Danandeh, A., Vozella, V., Lim, J., Oveisi, F., Ramirez, G. L., Mears, D. J., Wynn, G. H., & Piomelli, D. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5020-7 · Cited by 57
“…anxiety (Haller et al. 2009; Kathuria et al. 2003; Naidu et al. 2007) and depression (Bortolato et al. 2007; Gobbi et al. 2005; Haller et al. 2009; Kathuria et al. 2003; Naidu et al. 2007) and stimulates monoaminergic neurons in brain regions controlling mood and emotionality (Gobbi et al. 2005).”
BackgroundMethodResultInfluentialSelf-citationRoberts, C. J., Stuhr, K. L., Hutz, M. J., Raff, H., & Hillard, C. J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.026 · Cited by 54
“URB597 inhibits FAAH and produces significant increases in brain AEA (Kathuria et al., 2003), while JZL184 inhibits MAGL and increases brain 2-AG (Long et al.”
BackgroundClick Chemistry‐Led Advances in High Content Functional Proteomics
Salisbury, C. M., & Cravatt, B. F. (2007) · QSAR & Combinatorial Science · doi:10.1002/qsar.200740090 · Cited by 55
Hippocampal Metaplasticity Is Required for the Formation of Temporal Associative Memories
Xu, J., Antion, M. D., Nomura, T., Kraniotis, S., Zhu, Y., & Contractor, A. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2869-13.2014 · Cited by 57
“The doses of URB597 were chosen based on previous studies demonstrating that intraperitoneal administration can effectively inhibit FAAH activity in brain (Kathuria et al., 2003).”
BackgroundN -acyl taurines are endogenous lipid messengers that improve glucose homeostasis
Grevengoed, T. J., Trammell, S. A. J., McKinney, M. K., Petersen, N., CARDONE, R. L., Svenningsen, J. S., Ogasawara, D., Nexøe-Larsen, C., Knop, F. K., Schwartz, T. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916288116 · Cited by 58
An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters
Moise, A. M., Eisenstein, S. A., Astarita, G., Piomelli, D., & Hohmann, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1209-5 · Cited by 62
“Inhibition of FAAH elevates brain anandamide levels and suppresses anxiety-related behaviors in rats and mice (Bortolato et al. 2007; Fegley et al. 2005; Kathuria et al. 2003; Moreira et al. 2008).”
BackgroundMethodResultSelf-citationRoche, M., Kelly, J. P., O’Driscoll, M., & Finn, D. P. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02838.x · Cited by 60
Ghosh, S., Kinsey, S. G., Liu, Q.-S., Hruba, L., McMahon, L. R., Grim, T. W., Merritt, C. R., Wise, L. E., Abdullah, R. A., Selley, D. E., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.222851 · Cited by 54
“Blockade of either enzyme produces antinociceptive effects in a variety of acute and chronic preclinical models of pain (Kathuria et al., 2003; Chang et al., 2006; Jhaveri et al., 2007; Russo et al., 2007; Kinsey et al., 2009; Spradley et al., 2010; Guindon et al., 2011, 2013; Ghosh et al., 2013).”
BackgroundCannabinoid treatments in epilepsy and seizure disorders
Devinsky, O., Jones, N. A., Cunningham, M. O., Jayasekera, B. A. P., Devore, S., & Whalley, B. J. (2023) · Physiological Reviews · doi:10.1152/physrev.00049.2021 · Cited by 59
Solorzano, C., Antonietti, F., Duranti, A., Tontini, A., Rivara, S., Lodola, A., Vacondio, F., Tarzia, G., Piomelli, D., & Mor, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100582w · Cited by 54
Self-citationEffects of endocannabinoid and endovanilloid systems on aversive memory extinction
Laricchiuta, D., Centonze, D., & Petrosini, L. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.010 · Cited by 58
Hossain, M. Z., Ando, H., Unno, S., & Kitagawa, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041423 · Cited by 63
Biosynthesis and Fate of Endocannabinoids
Cascio, M. G., & Marini, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_2 · Cited by 60
Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats
Lim, J., Igarashi, M., Jung, K., Butini, S., Campiani, G., & Piomelli, D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.284 · Cited by 54
Self-citationA Genetic Component to National Differences in Happiness
Minkov, M., & Bond, M. H. (2016) · Journal of Happiness Studies · doi:10.1007/s10902-015-9712-y · Cited by 53
“Algeria Estimate based on converging data for Algerian Mozabites (Berbers) in Kidd (2014) and Palestinian Arabs in Kidd (2014) Andorra Estimate based on converging data for Spain in De Luis et al.”
BackgroundMethodInfluentialA pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase
Carey, L. M., Slivicki, R. A., Leishman, E., Cornett, B., Mackie, K., Bradshaw, H. B., & Hohmann, A. G. (2016) · Molecular Pain · doi:10.1177/1744806916649192 · Cited by 55
“Since its discovery in 1993,(3) FAAH has gained considerable attention as a therapeutic target.(4,5) Inhibitors of FAAH produce therapeutic effects in a variety of pathophysiological conditions including anxiety,(5) depression,(6) and neuropathic and inflammatory pain.”
BackgroundSu, S., Wang, Y.-Q., Wu, Y., Wang, D., Lin, Q. D., & Hai, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.009 · Cited by 56
Romero‐Sanchiz, P., Nogueira‐Arjona, R., Pastor, A., Araos, P. F., Serrano, A., Boronat, A., García‐Marchena, N., Mayoral, F., Bordallo-Aragón, A., Alén, F., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.026 · Cited by 55
Anandamide hydrolase: a guardian angel of human reproduction?
Maccarrone, M., & Finazzi‐Agrò, A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.05.002 · Cited by 56
Hasanein, P., & Far, M. T. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.007 · Cited by 57
“Finally, it should be noted that systemic injection of CB1 agonists would be expected to affect all populations of CB1 receptors, and therefore could produce CB1-mediated effects that are quite different from those produced by FAAH inhibitors or FAAH deletion, which presumably have a more specific effect, magnifying t…”
InfluentialFowler, C. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.02.005 · Cited by 54
Endocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow
Angelis, V. D., Koekman, A. C., Weeterings, C., Roest, M., de Groot, P. G., Herczenik, E., & Maas, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108282 · Cited by 55
Bedse, G., Colangeli, R., Lavecchia, A. M., Romano, A., Fabio Altieri, F., Cifani, C., Cassano, T., & Gaetani, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.005 · Cited by 58
“Such effects were not accompanied by the broad spectrum of cannabimimetic behavioral actions (Kathuria et al., 2003), and were associated to an increased firing of noradrenergic and serotonergic neurons, respectively, the locus coeruleus (LC) and the dorsal raphe of adult rats, and by an increase…”
InfluentialSelf-citationde Novellis, V., Luongo, L., Guida, F., Cristino, L., Palazzo, E., Russo, R., Marabese, I., D’Agostino, G., Calignano, A., Rossi, F., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.034 · Cited by 54
“It has been shown that FAAH inhibition elevates PEA levels (Jhaveri et al., 2008; Kathuria et al., 2003), which can also produce analgesia by activating PPAR-α (Lo Verme et al., 2006) and other mechanisms (Costa et al., 2008).”
Self-citationMileni, M., Garfunkle, J., Ezzili, C., Kimball, F. S., Cravatt, B. F., Stevens, R. C., & Boger, D. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9012196 · Cited by 58
Naidoo, V., Nikas, S. P., Karanian, D. A., Hwang, J., Zhao, J., Wood, J. T., Alapafuja, S. O., Vadivel, S. K., Butler, D., Makriyannis, A., et al. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9472-4 · Cited by 55
“Blocking cannabinergic inactivation is an avenue to promote such responses, and the hydrolase FAAH is a primary mediator of breaking down released endocannabinoids (Tsou et al. 1999; Cravatt et al. 2001; Egertova et al. 2003; Kathuria et al. 2003; Morozov et al. 2004).”
BackgroundMinkkilä, A., Savinainen, J. R., Käsnänen, H., Xhaard, H., Nevalainen, T., Laitinen, J. T., Poso, A., Leppänen, J., & Saario, S. M. (2009) · ChemMedChem · doi:10.1002/cmdc.200900137 · Cited by 60
Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice
Mereu, M., Tronci, V., Chun, L. E., Thomas, A. M., Green, J. L., Katz, J. L., & Tanda, G. (2013) · Addiction Biology · doi:10.1111/adb.12080 · Cited by 56
“), which blocks the metabolism of the endocannabinoid, anandamide (Kathuria et al. 2003).”
BackgroundCampolongo, P., Ratano, P., Manduca, A., Scattoni, M. L., Palmery, M., Trezza, V., & Cuomo, V. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00011 · Cited by 58
Self-citationClassical endocannabinoid‐like compounds and their regulation by nutrients
Kleberg, K., Hassing, H. A., & Hansen, H. S. (2014) · BioFactors · doi:10.1002/biof.1158 · Cited by 57
“Degradation Fatty acid amide hydrolase (FAAH) is the major enzyme responsible for degradation of NAEs, and accumulated levels of NAE has been reported in tissues with decreased FAAH activity, as in FAAH knockout mice [45,46] or via FAAH inhibition [45,47,48].”
BackgroundRivera, P., Bîndilă, L., Pastor, A., Pérez‐Martín, M., Pavón, F. J., Serrano, A., de la Torre, R., Lutz, B., de Fonseca, F. R., & Suárez, J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00098 · Cited by 57
“The FAAH inhibitor URB597 (KDS-4103) selectively blocks AEA hydrolysis in neurons without having any inhibitory effect on AEA transport (Kathuria et al., 2003; Piomelli et al., 2006).”
BackgroundDesroches, J., Charron, S., Bouchard, J., & Beaulieu, P. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.006 · Cited by 54
“, 2008) via CB1 (URB597; (Kathuria et al., 2003) and CB1/CB2 (URB602; (Hohmann et al.”
BackgroundInfluential
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.